Stem Cell Study for Patients With Heart Failure

This study has been withdrawn prior to enrollment.
(Funding not obtained. No subjects enrolled.)
Information provided by:
Losordo, Douglas, M.D. Identifier:
First received: June 27, 2006
Last updated: September 10, 2010
Last verified: September 2010
The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms.

Condition Intervention Phase
Myocardial Ischemia
Congestive Heart Failure
Cardiovascular Disease
Biological: Autologous Stem Cells
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%

Resource links provided by NLM:

Further study details as provided by Losordo, Douglas, M.D.:

Primary Outcome Measures:
  • The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: September 2010
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Stem Cells
Biological: Autologous Stem Cells
Intramyocardial injections
Placebo Comparator: 2
Biological: Autologous Stem Cells
Intramyocardial injections


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects greater than 21 years old.
  • Subjects with functional class (NYHA) III ischemic heart failure.
  • Subjects who have attempted "best" cardiac medical therapy including long-acting nitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-converting enzyme inhibitors without control of symptoms.
  • Subjects must be identified as non-candidates for conventional revascularization by their referring cardiologist. The patient's angiogram will then be reviewed by an independent interventional cardiologist and independent cardiac surgeon to determine if the patient is eligible for revascularization.
  • Subjects must have left ventricular ejection fraction <40% by echocardiography.
  • All subjects must have a recent coronary angiogram (within the last 1 year) to document the coronary anatomy and insure the presence of coronary disease that is not amenable to standard revascularization procedures.
  • Have serum B-type Natriuretic Peptide (BNP) level >100 pg/ml.

Exclusion Criteria:

  • Myocardial infarction (Q wave or non-Q wave defined as CKMB >3 times normal) within 30 days of treatment.
  • Successful coronary revascularization procedures within 3 months of study enrollment.
  • Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment.
  • NYHA Class I, II or IV heart failure and patients with idiopathic or non-ischemic heart failure.
  • History of severe aortic stenosis (aortic valve area < 1.0 cm2) or insufficiency (>2+); severe mitral stenosis (mitral valve area <1.5 cm2); or severe mitral insufficiency(>2+).
  • Implantation of biventricular pacemaker within 90 days of study treatment.
  • Severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary disease, renal failure or cancer).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346177

United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Losordo, Douglas, M.D.
Principal Investigator: Douglas W. Losordo, M.D. Northwestern University
  More Information

No publications provided

Responsible Party: Director, Feinberg Cardiovascular Research Institute, Program in Cardiovascular Regenerative Medicine, Northwestern University/Northwestern Memorial Hospital Identifier: NCT00346177     History of Changes
Other Study ID Numbers: BB-IND-11196-02 
Study First Received: June 27, 2006
Last Updated: September 10, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Losordo, Douglas, M.D.:
stem Cells
low EF
heart attack
congestive heart failure
cardiovascular disease
Heart Failure
Low Ejection Fraction

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Heart Failure
Myocardial Ischemia
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Pathologic Processes
Vascular Diseases processed this record on February 04, 2016